Track topics on Twitter Track topics that are important to you
Circadian Technologies Limited is an emerging leader in the field of angiogenesis-based treatments for cancer. Focusing on a class of drug targets called Vascular Endothelial Growth Factors (VEGFs), we seek to develop truly novel therapies to extend and improve the lives of cancer sufferers. Circadians strengths are the following:
Intellectual Property Circadian owns the worlds largest and most comprehensive intellectual property estate covering the key angiogenesis targets VEGF-C, VEGF-D and VEGFR-3. These IP rights include over 50 patent families, 200 granted patents and 500 patents pending worldwide.
Pipeline Circadian has an internal product pipeline comprising biologics-based drugs to three angiogenesis targets. Circadians most advanced program, VGX-100, an antibody-drug targeting VEGF-C, is expected to enter clinical trials in 2011.
Partners Circadian has commercial partnerships with other leading biotechnology companies for the development of products based on the companys technology. Ark Therapeutics is evaluating Trinam in Phase 3 clinical trials. ImClone Systems, a subsidiary of Eli Lilly and Company, is conducting preclinical studies of an anti-VEGFR-3 antibody for cancer treatment.
Management Circadian is run by some of the most experienced and successful people in the Australian biotechnology industry, with an extensive track record of success in product and business development. Members of Circadians leadership team have held past roles with Amgen, Genentech, GlaxoWellcome, Schering and Sanofi-Aventis, among other leading companies.
Financial strength Circadian has a strong financial position and substantial cash reserves.
Circadian Technologies was one of Australias earliest biotechnology companies and was listed on the Australian Stock Exchange in 1985. Originally functioning as a commercial vehicle for outstanding, diverse biomedical research, the company successfully launched and spun out many of Australias most well-known biotechnology companies including Axon Instruments, Optiscan Imaging and Antisense Therapeutics. In 2008 Circadian modified its strategy to focus on the development of biologics-based therapies for cancer, in particular leveraging the product pipeline and broad intellectual property assets of its 100 percent-owned subsidiary, Vegenics Pty Ltd. Vegenics Pty Ltd formally holds the intellectual property rights to develop Vascular Endothelial Growth Factor (VEGF)-based therapies.
Source: Circadian Technologies
10 Wallace Avenue
Phone: 61 3 9826 0399
Fax: 61 3 9824 0083
DNA replication regulates nucleosome dynamics at the promoter of a negative element of the circadian clock, thereby providing regulatory feedback into circadian rhythms.
The award of the 2017 Nobel Prize in Physiology or Medicine has piqued public and scientific interest in circadian research (see Nature550, 18;10.1038/nature.2017.227362017). The time has come to tran...
Can environmental toxins disrupt circadian rhythms - the biological "clock" whose disturbance is linked to chronic inflammation and a host of human disorders? Research showing a link between circadian...
Animal studies show how stress disrupts circadian rhythms and sleep patterns and indicate a possible treatment approach.
A set of core clock proteins organize themselves into a handful of molecular machines that control the precise workings of the body's circadian rhythms, new research has found.
Is this another youth craze, like the Harlem shuffle?I think you mean the Harlem shake. But no—it’s not one of those crazy dances sweeping social media. The circadian rhythm is what you and I call...
Disruption to our innate circadian rhythms, or biological clocks, has been linked with a wide range of human disorders. New studies with the tiny aquatic zooplankton Daphnia raise the question of whet...
A person's ability to smell may vary throughout the day in accordance with their circadian rhythm, according to new evidence in a small study by researchers who are looking at how sleep may influence ...
BIO-CORNEUM HC Advanced Scar Supervision Anti-Itch Gel
Omeprazole Delayed Release Tablets, 20 mg
Synchrony of circadian rhythms between tissues/organs appears critical for health. A new study reports that meal timing, a modifiable temporal cue for the circadian system, can selectively uncouple ci...
Circadian rhythm exerts its influence on animal physiology and behavior by regulating gene expression at various levels. Here we systematically explored circadian long non-coding RNAs (lncRNAs) in mou...
To investigate circadian gene expressions in the mouse bladder urothelium to establish an experimental model and study the functions of the circadian rhythm.
The endogenous circadian rhythms are one of the cardinal processes that control sleep. They are self-sustaining biological rhythms with a periodicity of approximately 24 hours that may be entrained by...
In mammalian corneal epithelium, mitosis shows a distinct circadian pattern. However, how this circadian pattern is maintained, and how it or its disruption influence renewal and regeneration remain u...
The objective of this pilot study is to test the feasibility of a larger planned trial. The objective of this larger trial will be to determine the extent to which aspects of circadian rhy...
The purpose of this study is to assess the safety and efficacy of VEC-162 compared to matching placebo on circadian phase shift and sleep parameters.
Europe is undergoing a demographic change with a rapidly growing population of 65 years+. This challenges municipalities and hospitals as the ageing citizens need care and treatment due to...
The circadian rhythm of copeptin will be examined in healthy subjects.
The purpose of this study is to investigate the impact of exposure to ergonomic circadian light on physiological and mental parameters in stroke patients admitted for rehabilitation.
Circadian Technologies Limited is an emerging leader in the field of angiogenesis-based treatments for cancer. Focusing on a class of drug targets called Vascular Endothelial Growth Factors (VEGFs),...
Reset, a discovery-stage biopharma company co-founded by leaders in the field of circadian biology and Bay City Capital, is developing first-in-class approaches to treating diseas...
Temperature readings of breast tissue create Dynamic Thermal Finger Prints (DTFP) which are correlated to dysfunctional circadian genes. Multiple bioinformatics algorithms compare...
Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...
Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...
We have published hundreds of Circadian Technologies Limited news stories on BioPortfolio along with dozens of Circadian Technologies Limited Clinical Trials and PubMed Articles about Circadian Technologies Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Circadian Technologies Limited Companies in our database. You can also find out about relevant Circadian Technologies Limited Drugs and Medications on this site too.
Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers) - Mouth cancer can develop on the lip, the tongue, the floor...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells. In vertebrates, it is composed of blo...